These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16800098)

  • 1. Do intensive care patients need an individualized dosing regimen for levofloxacin?
    Tayab ZR; Hochhaus G; Kaufmann S; Jäger D; Barth J
    Int J Clin Pharmacol Ther; 2006 Jun; 44(6):262-9. PubMed ID: 16800098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia.
    Pea F; Di Qual E; Cusenza A; Brollo L; Baldassarre M; Furlanut M
    Clin Pharmacokinet; 2003; 42(6):589-98. PubMed ID: 12793843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit.
    Rebuck JA; Fish DN; Abraham E
    Pharmacotherapy; 2002 Oct; 22(10):1216-25. PubMed ID: 12389872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia.
    Pea F; Pavan F; Di Qual E; Brollo L; Nascimben E; Baldassarre M; Furlanut M
    J Chemother; 2003 Dec; 15(6):563-7. PubMed ID: 14998081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
    Zhang J; Xu JF; Liu YB; Xiao ZK; Huang JA; Si B; Sun SH; Xia QM; Wu XJ; Cao GY; Shi YG; Zhang YY
    J Infect Chemother; 2009 Oct; 15(5):293-300. PubMed ID: 19856067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia.
    Boselli E; Breilh D; Rimmelé T; Djabarouti S; Saux MC; Chassard D; Allaouchiche B
    Crit Care Med; 2005 Jan; 33(1):104-9. PubMed ID: 15644655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia.
    Benko R; Matuz M; Doro P; Peto Z; Molnar A; Hajdu E; Nagy E; Gardi J; Soos G
    Int J Antimicrob Agents; 2007 Aug; 30(2):162-8. PubMed ID: 17570646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does Critical Illness Change Levofloxacin Pharmacokinetics?
    Roberts JA; Cotta MO; Cojutti P; Lugano M; Della Rocca G; Pea F
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1459-63. PubMed ID: 26666946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis.
    Czock D; Hüsig-Linde C; Langhoff A; Schöpke T; Hafer C; de Groot K; Swoboda S; Kuse E; Haller H; Fliser D; Keller F; Kielstein JT
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1263-8. PubMed ID: 17699357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levofloxacin pharmacokinetics in adult cystic fibrosis.
    Lee CKK; Boyle MP; Diener-West M; Brass-Ernst L; Noschese M; Zeitlin PL
    Chest; 2007 Mar; 131(3):796-802. PubMed ID: 17356095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
    Roberts JA; Lipman J
    Crit Care Med; 2013 Feb; 41(2):489-95. PubMed ID: 23263583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.
    Abdul-Aziz MH; Abd Rahman AN; Mat-Nor MB; Sulaiman H; Wallis SC; Lipman J; Roberts JA; Staatz CE
    Antimicrob Agents Chemother; 2016 Jan; 60(1):206-14. PubMed ID: 26482304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
    Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
    Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration.
    Hansen E; Bucher M; Jakob W; Lemberger P; Kees F
    Intensive Care Med; 2001 Feb; 27(2):371-5. PubMed ID: 11396281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects.
    Conte JE; Golden JA; McIver M; Zurlinden E
    Int J Antimicrob Agents; 2006 Aug; 28(2):114-21. PubMed ID: 16837169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.
    Kiser TH; Hoody DW; Obritsch MD; Wegzyn CO; Bauling PC; Fish DN
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1937-45. PubMed ID: 16723549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study.
    Lemaitre F; Fily F; Foulquier JB; Revest M; Jullien V; Petitcollin A; Tattevin P; Tron C; Polard JL; Verdier MC; Comets E; Huten D; Arvieux C; Bellissant E; Laviolle B
    Biomed Pharmacother; 2021 Oct; 142():112053. PubMed ID: 34435591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elimination of levofloxacin in critically ill patients with renal failure: influence of continuous veno-venous hemofiltration.
    Bellmann R; Egger P; Gritsch W; Bellmann-Weiler R; Joannidis M; Dunzendorfer S; Wiedermann CJ
    Int J Clin Pharmacol Ther; 2002 Apr; 40(4):142-9. PubMed ID: 11996208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.
    Burgess DS; Hall RG
    Clin Ther; 2007 Jul; 29(7):1421-7. PubMed ID: 17825693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves.
    Dumka VK
    J Vet Sci; 2007 Dec; 8(4):357-60. PubMed ID: 17993749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.